Novel factor XI inhibitors for postoperative VTE prophylaxis: Breakthroughs and insights from the ROXI-VTE-I and ROXI-VTE-II trials

The Innovation Medicine · Published 2026-01-01 · DOI 10.59717/j.xinn-med.2026.100222

Free full text

Authors being retrieved — see the publisher record. https://doi.org/10.59717/j.xinn-med.2026.100222

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Related articles

• Rising PM2.5 variability fuels mortality from pollution extremes · The Innovation Medicine · 2026 · Same journal
• High-signal drug assessment for drug-related aortic aneurysm and dissection rupture: Evidence from real-world databases and animal experiments · The Innovation Medicine · 2026 · Same journal
• Improving population health post-COVID-19 by addressing interacting threats to health and the environment · The Innovation Medicine · 2026 · Same journal
• Tandem mass spectrometry in newborn screening for inherited metabolic diseases: A comprehensive review · The Innovation Medicine · 2026 · Same journal
• Semaglutide in obesity-related knee osteoarthritis: Interpreting STEP 9 and implications for practice · The Innovation Medicine · 2026 · Same journal
• Vascular complications in early-onset type 2 diabetes in China: An emerging challenge · The Innovation Medicine · 2026 · Same journal
• From aspirin to clopidogrel monotherapy: A new paradigm for secondary prevention in coronary artery disease · The Innovation Medicine · 2026 · Same journal
• Precision management of acute myeloid leukemia: A unified guideline of international and regional standards · The Innovation Medicine · 2026 · Same journal
• A global systematic analysis and statistical evaluation of prognostic prediction models for non-small cell lung cancer · The Innovation Medicine · 2026 · Same journal
• TNF/TNFR modulates the Traf2-Gαs axis to promote aging-related bone loss and impair PTH (1-34) efficacy · The Innovation Medicine · 2026 · Same journal